In local news, COFEPRIS authorized the sale of dozens of cannabis-derived products and the Ministry of Health of Mexico City signed agreements aimed toward reparations for victims of human right abuses. The future Minister of Health claims that the new administration will integrate the services of IMSS, ISSSTE and PEMEX, while Mexico’s diabetes epidemic continues rising and now affects 12 million people.
In international news, Congo’s Ebola outbreak is affecting newborn babies and children under two years of age. Novartis and a benefits manager debate on the price of an orphan drug for spinal muscular atrophy and Bayer is to make its studies on glyphosate, a weedkiller implicated in thousands of lawsuits, public in an effort to defend itself.
Mexico Health Review spoke to Mariano de Elizalde, CEO of Sandoz Mexico, on the product lines Sandoz is introducing to the Mexican generics market.
Now jump into last week’s highlights:
COFEPRIS authorized the sale of 38 cannabis-derived products, which include 21 food supplements, nine cosmetics, six foodstuffs and two raw materials.
The future Minister of Health, Jorge Alcocer, told media that the new administration will try to integrate the services of the three major healthcare institutions: IMSS, ISSSTE and PEMEX.
Mexico has 12 million diabetics, said the Director General of Hospital Civil de Guadalajara, which means that about 10 percent of the population has this disease and this rate could climb to 17 percent by 2030.
The Ministry of Health of Mexico City signed four conciliatory agreements that permit the recognition of responsibility and reparation to victims with the Human Rights Commission of Mexico City.
The UN warns that recent Ebola outbreak in Congo is starting to affect babies younger than two. Ebola is typically transferred through infected body fluids and thus affects mainly adults. The recent cases are leading doctors to believe the disease is being transmitted by breast milk.
Novartis and benefits manager Express Scripts are debating the value of the pharmaceutical’s new one-time drug to treat spinal muscular atrophy, a rare disease. Novartis proposed the drug’s US$4-5 million price tag, which Express Scripts calls unsustainable.
Bayer continues to face the fallout from its acquisition of Monsanto as the 9,300 lawsuits against Monsanto’s weedkiller Roundup, which contains glyphosate, continue to hit the pharmaceutical’s shares. The pharmaceutical vowed to defend itself, citing hundreds of reports that claim glyphosate is safe and will provide public access on its own glyphosate studies.